Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (356)	12/31/2000 11:58:22 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2243

continuing...... The granddaddy/momma of them all, "T/FIF" finally has all components green. Left wallowing with well over 50% of assets in cash, it's now up 468% on the back of 18-bagger OSIP.......... siliconinvestor.com include standard GLIA-related disclaimer from this point on......... Again once left wallowing largely in cash, "margin-pain" has performed! Five components, no losers, a 20-bagger...... siliconinvestor.com "dry-powder" finished 2000 at plus 461% with two 11-baggers (NPSP and TTP). Fifteen components, one loser........ siliconinvestor.com "neuro" ends year 2000 at plus 339%, three losers and a 10-bagger......... siliconinvestor.com

To: scaram(o)uche who wrote (356)	1/1/2001 2:22:45 AM
From: scaram(o)uche	Respond to of 2243

BIOTECH INVESTOR OF THE YEAR, 2000 SI biotech is a collaborative effort among scientists and non-scientists who share a passion for the mixture of big science with sound business strategies. Everyone is welcome, leave the bull at the door. The best biotech analysis available -- anywhere, at any price -- is found here at SI. 1998 was a tough year for biotech, particularly for small caps. At the end of the year, the strategy of three individuals stood out. Their performance was spectacular -- not above average, but SPECTACULAR. Furthermore, it was documented and archived. I felt compelled to state the obvious, that Vector 1, Peter Suzman and Jim Silverman were 1998's biotech investors of the year. I didn't plan to make it -- an arrogant pronouncement -- an annual event. In 1999, however, there was an individual whose performance made the rest of our great 99s look like child's play. His performance was also documented and archived. I therefore opted for arrogance (anyone surprised?); Dr. Miljenko Zuanic was OBVIOUSLY the best of biotech investors for '99. Now it's tradition. Year 2000 was a romp. Money washed over the sector, cash looking for a "ride home" from dotcom insanity. New business strategies were born. Quick-witted CFOs held out their arms, facilitating global changes in the nature of biotech-pharma interactions. Biologicals -- largely antibodies -- did a great job of sharing the stage with small molecules. New business strategies, new companies, new liquidity. But one thing didn't change...... 1998 Vector 1, Jim Silverman, Peter Suzman 1999 Miljenko Zuanic 2000 Miljenko Zuanic Apart from congratulations, no discussion allowed. :-) Thanks to all contributors for another year of help and collaboration. Best for the New Year to contributors and lurkers alike! Rick